AzTrials
AzTrials

Pancreatic DiseaseDRAINAGE DPCNCT01368094

Early (4 Days) Versus Standard Drainage of the Abdominal Cavity After Pancreaticoduodenectomy

A study testing Drain removal at D4 and Standard drain removal in people with Pancreatic Disease and Pancreatic Neoplasms, run by Centre Hospitalier Universitaire, Amiens at 5 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Around two thousand pancreaticoduodenectomy (PD) are performed each year in France. This intervention is associated with a high rate of postoperative complications including: pancreatic fistulas (PF); surgical site infections (intra-abdominal abscess, wound infection); delayed gastric emptying (gastroparesis); and… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pancreatic Disease, Pancreatic Neoplasms
What is being tested?
Drain removal at D4 and Standard drain removal
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
141 participants
Where
5 sitesFrance
Study dates
Jun 2011to Jan 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Pancreatic tumor regardless of its nature: All patients requiring PD (following thesaurus or multidisciplinary team council recommendation) for this indication will be included.
  • Ability to participate in a clinical research protocol.
  • Given informed consent.

Who cannot join

  • History of pancreatic surgery or biliary diversion and / or digestive
  • Patient taken in charge for chronic pancreatitis without tumor
  • History of supramesocolic radiotherapy
  • Sick supported emergency
  • Physical or mental condition does not allow participation in the study
  • Contra-indication to surgery
Show all 10Show fewer
  • ASA classification (American Society of Anesthesiologists) IV-V or life expectancy <48
  • Pregnancy or breastfeeding
  • Patient under guardianship or private patient of liberty by a judicial or administrative decision
  • Age under 18yo

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

France5 sites
  • CHU Amiens

    Amiens, Picardie, 80000

  • Centre Hospitalier de Beauvais

    Beauvais, 60000

  • Centre Hospitalier Saint-Martin

    Caen, 14050

  • Centre Hospitalier Régional Universitaire Claude Huriez

    Lille, 59037

  • Centre Hospitalier Charles Nicolle

    Rouen, 76 031

Other trials in France

About this study

Official title: Early (4 Days) Versus Standard Drainage Removal of the Abdominal Cavity After Pancreaticoduodenectomy- - A Randomized Multicenter Study

Around two thousand pancreaticoduodenectomy (PD) are performed each year in France. This intervention is associated with a high rate of postoperative complications including:

  • pancreatic fistulas (PF);
  • surgical site infections (intra-abdominal abscess, wound infection);
  • delayed gastric emptying (gastroparesis);
  • and hemorrhage.
Read more

The incidence of SSI (superficial and deep) is about 35% and seems influenced by the prolonged intra-abdominal drainage. For several years, there has been a global trend to reduce the use of abdominal drainage after abdominal surgery. Several randomized clinical trials have shown that prophylactic drainage does not decrease the incidence of postoperative complications during elective hepatectomy, colectomy, and cholecystectomy and could increase the number of SSI. However, the role of prophylactic drainage after PD is so far unclear.

The aim of this prospective randomized multicenter study is to evaluate the influence of early (4 days) versus standard (10 to 15 days, depending on the staff clinical practice) drainage removal of the abdominal cavity after PD, on the rate of SSI.

Materials and Methods: The technique of PD is left at the discretion of the operator as well as the prescription of analogues of somatostatin. Drainage of the abdominal cavity is made of one or two round silicone close suction drains or open multichannel silicone drains placed in the vicinity of the pancreatic and biliary anastomosis. Shall be excluded patients operated on for chronic pancreatitis and patients who underwent preoperative radiotherapy. The 3rd postoperative day, a fistula is sought clinically, biologically and on CT-scanner images. In case of pancreatic fistula, the patient is excluded from randomization and drainage of the abdominal cavity is left in place depending on the different teams' practice. Patients without fistula are randomized to either drainage removal 4 days after surgery (D4) or standard drainage.

Read the detailed description

Introduction. Two thousand pancreaticoduodenectomy (PD) are performed per year in France (observatory pancreatectomy GCB 2005). This intervention is associated with a high rate of postoperative complications including pancreatic fistula (PF), the site infections (SSI: intra-abdominal abscess, wound infection), gastroparesis, and hemorrhage. The incidence of SSI (superficial and deep) is about 35% and seems influenced by the prolonged drainage of intra-abdominal. For several years, there is a global trend to reduce the use of abdominal drainage after abdominal surgery. Several randomized clinical trials have shown that prophylactic drainage does not decrease the incidence of postoperative complications during elective hepatectomy, colectomy, and cholecystectomy and could increase the number of SSI. However, the role of prophylactic drainage after PD is so far unclear. In the literature, three studies have examined the influence of drainage of the abdominal cavity after PD, and were published at the time this protocol was submitted :

  • The study of Conlon et al. (Ann Surg 2001), prospective randomized study comparing no drainage standard abdominal drainage. The SSI rates in the drained group was 36% versus 16% in the undrained group (NS, but in his critical study methodology).
  • The study of Kawai et al. (Ann Surg 2006), non-randomized prospective study comparing short drainage (D4) drainage standard (D8). The SSI rates in the drained group was 38% versus 7.7% in the undrained group (significant but non-randomized study involving patients on two consecutive periods).
  • Study Berberat et al. (Büchler) (J Gastrointest Surg 2007), retrospective analysis of a population of patients with a PD (80%) the results by intention to treat the early removal of drainage of the abdominal cavity. The SSI rates published in this study is 9.4%.

After acceptance of this protocol by local ethics committee, a forth study was published by Bassi et al (Bassi C Ann Surg 2010) : it is a randomized controlled study. Patients who underwent pancreatic resection (including left pancreatic resection) and at low risk of postoperative pancreatic fistula were randomized on post operative day (POD) 3 to receive either early (POD 3) or standard drain removal (POD 5 or beyond). The primary end point of the study was the incidence of pancreatic fistula. This study shows that, in patients with a low risk of pancreatic fistula after pancreatic resection, intra-abdominal drains can be safely removed on POD 3 after standard pancreatic resections. A prolonged period of drain insertion is associated with a higher rate of postoperative complications with increased hospital stay.

The aim of the present prospective randomized multicenter study is to evaluate the influence of short drainage (4 days) of the abdominal cavity versus standard drainage (10 to 15 days, depending on the staff clinical practice) after PD on the rate of SSI.

Materials and Methods: The technique of PD is left at the discretion of the operator as well as the prescription of analogues of somatostatin. Drainage of the abdominal cavity is made of one or two round silicone close suction drains or open multichannel silicone drains placed in the vicinity of the pancreatic and biliary anastomosis. Shall be excluded patients operated on for chronic pancreatitis and patients who underwent preoperative radiotherapy. The 3rd postoperative day, a pancreatic fistula is sought clinically, biologically and on CT-scanner images. In case of pancreatic fistula, the patient is excluded from randomization and drainage of the abdominal cavity is left in place depending on the different teams' practice. Patients without fistula are randomized to either drainage removal 4 days after surgery (D4) or standard drainage.

Analysis and outcomes: The primary endpoint will be the occurrence of surgical site infection (SSI) at D30, as defined by:

  • surface SSI (wound abscess): infection of the skin, subcutaneous tissue or muscle, above the fascia, located at a surgical incision. The diagnosis is based on at least one of the following criteria:
  • The fluid from the wound or drain located above the fascia is purulent
  • A spontaneous dehiscence of the wound
  • A positive culture from a closed wound.
  • deep SSI (intra-abdominal abscess) infection in operated tissues or in site of intervention (under the fascia). The diagnosis is based on at least one of the following criteria:
  • The fluid from a drain positioned beneath the fascia is purulent;
  • A culture from a closed wound is positive;
  • Other signs of infection on direct examination found during a re-operation.

Secondary outcomes will be the length of hospital stay, postoperative complications, with emphasis on classification IIIa (radiological drainage) and IIIb (re-intervention) of Clavien (Dindo et al. Ann Surg 2004).

All patients who underwent PD during the study period, especially patients excluded before randomization will be collected.

Calculating the number of patients needed to reduce SSI rate from 30% (in the group standard drainage of the abdominal cavity) to 10% (in the short drainage group), with a risk alpha of 0.05 and a risk beta of 0.20 yields 124 patients. Taking into account 10% of patients not analyzable, the number of patients included in this study is 138 (69 patients in each arm).

Five university hospitals are participating in the study (Amiens, Lille, Caen, and Rouen) and one general hospital (CH Beauvais). The expected duration of the study is 24 months (12-14 patients per center per year).

Being tested
Drain removal at D4, Standard drain removal
Keywords
Pancreaticoduodenectomy, Drainage, Surgical site infection
Medical subject headings
Pancreatic Diseases, Pancreatic Neoplasms, Surgical Wound Infection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Drain removal at D4Procedure or surgery

    If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.

  • Standard drain removalProcedure or surgery

    If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.

Study groups in NCT01368094
Study groupRoleWhat they receive
Standard drainageActive comparatorNot described
Receives: Procedure: Standard drain removal
Short drainageExperimentalNot described
Receives: Procedure: Drain removal at D4

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Surgical Site Infection at D30

    The outcome measure is the occurrence of surgical site infection (SSI) at D30, as defined by:

    • surface SSI (wound abscess): infection of the skin, subcutaneous tissue or muscle, above the fascia, located at a surgical incision.
    • deep SSI (intra-abdominal abscess) infection in operated tissues or in site of intervention (under the fascia).

    Measured: 30 days after surgical intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jun 2011 (estimated)
  2. Study startJun 2011
  3. Primary completionJan 2016
  4. Study completionJan 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
141 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01368094
Sponsor's protocol ID
PHRCIR10-PR-REGIMBEAU
Other IDs
2010-A01347-32
Acronym
DRAINAGE DPC
Status last verified
Sep 2025
First submitted
6 Jun 2011
Last updated
19 Sep 2025
Results posted
No
Data monitoring committee
No

Publications

  • Dembinski J, Mariette C, Tuech JJ, Mauvais F, Piessen G, Fuks D, Schwarz L, Truant S, Cosse C, Pruvot FR, Regimbeau JM. Early removal of intraperitoneal drainage after pancreatoduodenectomy in patients without postoperative fistula at POD3: Results of a randomized clinical trial. J Visc Surg. 2019 Apr;156(2):103-112. doi: 10.1016/j.jviscsurg.2018.06.006. Epub 2019 Jan 31.

    PubMed 30713100

Questions about this trial

What is this clinical trial studying?

A study testing Drain removal at D4 and Standard drain removal in people with Pancreatic Disease and Pancreatic Neoplasms, run by Centre Hospitalier Universitaire, Amiens at 5 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Surgical Site Infection at D30 (time frame: 30 days after surgical intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01368094, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in